Prescient Therapeutics (ASX:PTX) to begin three next-gen CAR T programs
Prescient Therapeutics (PTX) has announced three internal development programs for its immune receptor technology platform,...
Prescient Therapeutics (PTX) has announced three internal development programs for its immune receptor technology platform,...
Following more than a decade of treatments, cancer survivor Laurie Adami now plans to tackle...
An American woman who owes her life to a bespoke cancer treatment is speaking out...
Laurie Adami has had a long and intricate journey with blood cancer, after being diagnosed...
In the battle against blood cancer, chimeric antigen receptor T cell (CAR-T) therapy is proving...
Special Report: A form of immunotherapy that involves modifying a patient’s white blood cells so...
Today, we will acquaint you with the product pipeline of ASX-listed clinical-stage biotechnology company Prescient Therapeutics...
StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each...
When local synthetic antibiotics developer Recce Pharmaceuticals announced they had entered into an antiviral Sars-CoV-2...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.